Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burggraaf, J
Right arrow Articles by Blauw, G J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burggraaf, J
Right arrow Articles by Blauw, G J
Thorax 2001;56:567-569 ( July )

Short paper

Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients J Burggraafa, R G J Westendorpc, J C C M in`t Veenb, R C Schoemakera, P J Sterkb, A F Cohena, G J Blauwc

a Centre for Human Drug Research, Zernikedreef 10, 2333 CL Leiden, The Netherlands, b Department of Pulmonology, Leiden University Medical Center, c Department of General Internal Medicine, Leiden University Medical Center

Correspondence to: Dr J Burggraaf kb{at}chdr.nl

Received 6 April 2000; Returned to authors 18 September 2000; Revised version received 4 December 2000; Accepted for publication 19 March 2001

BACKGROUND---Beta-2 adrenoceptor agonists have been associated with sudden death in asthma patients but the cause and underlying mechanism are unclear. Animal experiments indicate that the combination of hypoxia and beta 2 agonists may result in detrimental cardiovascular effects. A study was undertaken to investigate the effect of hypoxia on the systemic vascular effects of salbutamol in patients with asthma who are hypoxic by assessing forearm blood flow (FBF) as a measure of peripheral vasodilatation.
METHODS---Eight men with mild asthma underwent the following treatments: normoxia + placebo (NP), normoxia + salbutamol (NS), hypoxia + placebo (HP), and hypoxia + salbutamol (HS). The period of mask breathing started at t=0 minutes, lasted for 60 minutes, and at 30 minutes 800 µg salbutamol was inhaled. The experiment was completed 30 minutes after the inhalation (t=60 minutes). For the hypoxia treatment the SpO2 level was 82%. Differences between treatments were sought using factorial ANOVA on percentage change from the pretreatment value.
RESULTS---There were no significant differences in blood pressure and potassium levels between the treatments. After 60 minutes the increase in FBF was 13% (95% CI -12 to 39) more for HP treatment than for NP, 21% (95% CI -5 to 46) more for NS than for NP, and 32% (95% CI 7 to 58) more for HS than for HP (p=0.016). The inhalation of salbutamol during hypoxia resulted in a significant increase in FBF of 45% (95% CI 20 to 71) compared with NP (p=0.001).
CONCLUSION---Patients with asthma who are hypoxic and inhale beta 2 agonists have serious systemic vascular side effects which may be an additional explanation for the association between asthma treatment and sudden death.


Keywords: asthma; hypoxia; beta 2 agonists


© 2001 by Thorax



This article has been cited by other articles:


Home page
ChestHome page
J. J. Murray
Cardiovascular Risks Associated With {beta}-Agonist Therapy
Chest, June 1, 2005; 127(6): 2283 - 2285.
[Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
H W. Kelly
What Is New with the {beta}2-Agonists: Issues in the Management of Asthma
Ann. Pharmacother., May 1, 2005; 39(5): 931 - 938.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter
Cardiovascular Effects of {beta}-Agonists in Patients With Asthma and COPD: A Meta-Analysis
Chest, June 1, 2004; 125(6): 2309 - 2321.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
B J LIPWORTH
Revisiting interactions between hypoxaemia and {beta}2 agonists in asthma
Thorax, July 1, 2001; 56(7): 506 - 507.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2001 BMJ Publishing Group Ltd & British Thoracic Society